


Programm changes reserved



**Thank you
to our sponsors!**



Biotherapies for Life™



Recordati Rare Diseases - 1000 €

Octapharma - 600 €

CSL Behring - 500 €

Novartis - 400 €

SOBI - 500 €

Requests / Information:
carl-friedrich.classen@med.uni-rostock.de
Tel. +49 381 / 494 7255
Fax. +49 381 / 494 686 7255

The symposium will take place at the
**Kinder- und Jugendklinik,
Ernst-Heydemann-Str. 8, 18057 Rostock**




**A ZOOM-transmission is planned,
however quality cannot be guaranteed**

Login data and Abstract booklet will be sent
upon request.

**Kinder- und Jugendklinik der
Universitätsmedizin Rostock
Komm. Direktor Prof. Dr. M. Ballmann
Ernst-Heydemann-Str. 8
D - 18057 Rostock
AG Hirntumorforschung
Prof. Dr. med. Carl Friedrich Classen**



**Kinder- und Jugendklinik
Universitätsmedizin Rostock**



**19th ROSTOCK SYMPOSIUM
for Tumor Immunology and Brain
Tumor Research in Pediatrics
Friday 28 Feb. + Sat. 1 March 2025
Hörsaal
Kinder- und Jugendklinik der
Universitätsmedizin Rostock**

Programme

Friday 28. Feb. 2025

9:00 Welcome

Surgical Aspects of pediatric brain tumors of the hindbrain

Thomas Freiman, Rostock

CNS involvement in childhood ALL - past, present and future

Tomasz Ociepa, Szczecin

CD44/PHOX2B are markers for noradrenergic to mesenchymal transition and inform chemoimmunotherapy and EZH2-targeted treatment

Sascha Troschke-Meurer, Greifswald

Targeted combination therapy using CDK inhibitors and retinoic acid induces neuroblastoma cell differentiation

Larissa Lechermeier, Rostock

11:00-11:30 Coffee break

Target-mediated Drug Disposition impairs Anti-Neuroblastoma efficacy of high-affinity Anti-GD2 Antibodies in vitro

Sascha Troschke-Meurer, Greifswald

Tumor-treating fields for treatment of Colorectal Cancer

Zhaoran Su, Rostock

Chronic oxidative stress response and resistance in squamous cell carcinoma cells in vitro and in vivo

Julia Berner, Rostock

Efficacy and immunogenicity of medical gas plasma in actinic keratosis in vitro and ex vivo

Debora Singer, Rostock

13:00-14:00 Lunch break

miR signatures in Burkitt Lymphoma

Teresa Cardesa Salzmann, Rostock

microRNAs as markers in liquid biopsy and the case of miR-371-3 and C19MC

Jörn Bullerdiek, Rostock

Chemistry of RNA Therapeutics

Thomas Carell, München

16:00-16:30 Coffee break

Automating Science by generative AI: What can be done, what may be done, what must be done

Georg Fuellen, Rostock

An investigation of tumor heterogeneity and identification of immune cell subtypes in melanoma brain metastases

Josefine Radke, Greifswald

Science oriented career tracks in university medicine

Simone Fulda, Kiel

20:00 Dinner – networking and discussion

BORWIN Restaurant

Saturday March 1, 2025

9:00

Retrospective analysis of the clinical application of liquid biopsy in oncology

Julia Berghaus, Köln

Immune Checkpoint Blockade Augments Topotecan/Temozolomide and Anti-GD2-Based Chemoimmunotherapy to Overcome Resistance in High-Risk Neuroblastoma

Peter Moritz Ahrenberg, Greifswald

The velocity of temporal muscle wasting in cerebral metastasis is prognostic for poor survival

Artem Rafaelian, Rostock

Artificial Intelligence in Neuro-Oncology: Current Applications and Future Directions

Katherine Hewitt, Dresden

11:00 Coffee break

The complexity of malignant glioma treatment

Stefaan W. van Gool, Köln

Reelin' it in – is it possible to keep Glioblastoma cells from moving?

Philipp Heimann, Ulm

The Impact of SEC23A on 5-FU Chemotherapy Sensitivity and its Involvement in Endoplasmic Reticulum Stress-Induced Apoptosis in Colorectal Cancer

Menglan Liu, Rostock

Connexin 26 as a Key Mediator of Cellular Connectivity in Glioblastoma: Implications for Tumour Growth and Therapeutic Targeting

Andrew Westhoff, Ulm